The progression of solid tumors is highly dependent on the epidermal growth factor receptor (EGFR) pathway [5, 6], and cetuximab that targeting EGFR have demonstrated significant efficacy in advanced colorectal cancer and head and neck cancer [6]. This evidence concerns the gene EGFR and head and neck cancer.